Mankind Pharma Ltd.
NSE: MANKINDMankind Pharma Ltd.: A 30-second snapshot
Mankind Pharma's technical snapshot shows a price of ₹2,469.6, essentially at its 50-DMA (₹2,467.56) and about 8.4% above its 200-DMA (₹2,277.68), with a 1-year price change of -2.79% and a 3-month gain of 4.6%. Q1 results reported July 30 showed consolidated net profit of ₹568 crore, up 29.6% YoY, on revenue growth of 12.9%, alongside a mean analyst rating of 2.26 across 19 analysts (1-5 scale, lower = more constructive). Debt-to-equity stands at 0.38x with a rising trend flagged in the persistence data, against a quality score of 50 that ranks 2nd of 6 tracked pharma peers.
P/E
49.9
Forward P/E
34.7
ROE
—
Debt / Equity
38.11
Profit Margin
+13.9%
Div. Yield
+0.1%
5Y ROE > 15%
2/5
5Y FCF > 0
4/5
Quality
68/100
News
8 headlines · 5 positive · 0 negative
Mankind Pharma Q1 profit rises 30%, margins expand on strong domestic business - CNBC TV18
CNBC TV18
Mankind Pharma Q1 Consolidated Net Profit At 5.7B Rupees Vs 4.4B YoY - Sahi
Sahi
Mankind Pharma Q1 result: Profit rises 29.6% to ₹568 cr, revenue up 12.9% - Business Standard
Business Standard
Broker's Call: Mankind Pharma (Add) - BusinessLine
BusinessLine
Mankind Pharma Share Price Falls Over 5% Even As Q1 Profit Rises 29% - NDTV Profit
NDTV Profit
Recent context
- ·Q1 results reported July 30 showed consolidated net profit of ₹568 crore, up 29.6% YoY, on revenue growth of 12.9%, per CNBC-TV18, Business Standard and Sahi coverage.
- ·NDTV Profit reported the shares fell over 5% on results day even as profit rose 29%, a divergence from the otherwise positive news tone (5 positive, 3 neutral, 0 negative across 8 items).
- ·BusinessLine's July 7 'Broker's Call' column covered Mankind Pharma ahead of the Q1 results.
Strengths
- +Earnings grew faster than revenue over five years (29.6% vs 12.9%), pointing to margin or operating-leverage gains rather than growth funded purely by topline expansion.
- +Quality score of 50 ranks 2nd of 6 tracked pharma peers, behind Sun Pharma (56) but ahead of Apollo Hospitals (44), Max Healthcare (37), Cipla (28) and Dr. Reddy's (4).
- +Free cash flow was positive in 4 of the tracked years in the persistence data, and the stock trades above both its 50-DMA and 200-DMA.
- +Q1 results reported July 30 showed net profit of ₹568 crore, up 29.6% YoY, on revenue growth of 12.9%, with 5 of 8 recent news items carrying a positive sentiment tag and none negative.
Weaknesses
- −Debt-to-equity of 0.38x carries a 'rising' trend per the persistence data, consistent with acquisition-related financing tied to the Bharat Serums deal.
- −ROE exceeded 15% in only 2 of the tracked years and current-period ROE is not available in this dataset; the overall consistency score is 63/100.
- −Trailing PE of 49.93 sits roughly 9% above the approximate 6-stock peer-median PE (~45.8) and ranks 4th-cheapest of 6 peers tracked, with forward PE of 34.66 implying the market is pricing in continued earnings growth.
- −The technical snapshot's current price sits almost exactly at the 50-DMA and does not clearly reflect the >5% single-day decline reported in news coverage around the July 31 results date, so the price/RSI reading should be treated as approximate.
Open questions
- ?Does the rising debt-to-equity trend reflect one-off Bharat Serums acquisition financing that normalizes over time, or a structural shift in the balance sheet?
- ?What specifically drove the >5% single-day price decline on the Q1 results day despite profit growth of nearly 30% YoY?
- ?Does the gap between trailing PE (49.93) and forward PE (34.66) reflect a specific near-term earnings catalyst, and how has that gap historically closed for this stock?
- ?With ROE above 15% in only 2 of the tracked years, which business lines or cost items are driving the inconsistency in capital efficiency?
Peer comparison: Pharma
Ranks 2 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| MANKIND | Mankind Pharma Ltd.You're viewing | 49.9 | — | 50 |
| Industry avg | across 5 peers | 49.4 | +14.8% | 34 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.6 | +14.7% | 56 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 66.4 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 74.6 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.4 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 28.9 | +8.8% | 4 |
Technical state
Current price
₹2,469.60
SMA 50
₹2,467.56
SMA 200
₹2,277.68
RSI (14)
44.8 (neutral)
From 52w high
-7.6%
1Y return
-2.8%
3M return
+4.6%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- mediumDebt-to-equity is 0.38x (raw provider metric of 38.11 is percent-scaled, not an x-multiple) with a 'rising' trend flagged in the persistence data; the trajectory is consistent with acquisition-related financing tied to the Bharat Serums deal rather than an elevated absolute level.
- lowROE exceeded 15% in only 2 of the tracked years and current-period ROE is not available in this dataset; free cash flow was positive in 4 of the tracked years and the overall consistency score is 63/100.
- lowTrailing PE of 49.93 sits roughly 9% above the approximate 6-stock peer-median PE (~45.8) and ranks 4th-cheapest of 6 pharma peers tracked, while forward PE of 34.66 is materially lower, implying the market has priced in continued earnings growth.
- lowThe technical snapshot's current price (₹2469.6) sits almost exactly at the 50-DMA (₹2467.56) and does not clearly reflect the >5% single-day share price decline reported in news coverage around the July 31 results date; the real-time price and RSI reading should be treated as approximate rather than a same-day figure.
Cross-section contradictions
- News sentiment skews positive (5 positive, 3 neutral, 0 negative of 8 items) and includes Q1 profit growth of 29.6% YoY on 12.9% revenue growth, yet one headline (NDTV Profit) reports the shares fell over 5% on the results day itself, a divergence between the reported fundamentals and the immediate price reaction.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 11 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 1 Aug 2026 · rotates through NIFTY 500 every ~5 days